Emgality vs ajovy?

Short answer: Emgality (galcanezumab) and Ajovy (fremanezumab) are both preventive medicines for migraine that target the CGRP pathway, but they differ in dosing and a few specifics. Which is “better” depends on your preferences, medical history, and insurance.

Key differences at a glance

- Drug and mechanism
- Emgality: galcanezumab, targets CGRP ligand.
- Ajovy: fremanezumab, also targets CGRP ligand.
- (For comparison: Aimovig, erenumab, targets the CGRP receptor.)

- Dosing schedules
- Emgality: loading dose of 240 mg (given as two 120 mg injections) at start, then 120 mg once every month.
- Ajovy: can be given as 225 mg every month, or 675 mg every 3 months (three 225 mg injections at one time).

- Convenience
- If you hate monthly injections, Ajovy offers a quarterly option.
- Emgality requires a loading dose, then monthly injections.

- Efficacy
- Both have demonstrated meaningful reductions in monthly migraine days vs placebo in adults.
- Exact effect size varies by patient and migraine type (episodic vs chronic). There isn’t a clear winner; many people respond similarly, but some respond only to one product.

- Side effects and safety
- Common: injection-site reactions are common with both.
- Emgality has been associated with constipation; rare cases of more serious GI issues have been reported.
- Ajovy’s common side effects include injection-site reactions and upper respiratory infections; overall safety profiles are similar.
- Both are generally well tolerated; discuss any history of allergic reactions or prior drug antibodies with your clinician.

- Special indications
- Emgality is approved for migraine prevention and also for episodic cluster headache.
- Ajovy is approved for migraine prevention (episodic and chronic migraine). It does not have a cluster headache indication.

- Age and pregnancy considerations
- Both are approved for adults; pediatric data varies by product and country. Talk to a clinician about age eligibility and pregnancy/breastfeeding if relevant.

What to consider when choosing
- Dosing preference: prefer monthly injections after a loading dose (Emgality) vs monthly vs quarterly dosing (Ajovy).
- Tolerance for constipation risk (higher with Emgality).
- Need or desire for a cluster headache option (Emgality has this indication).
- Insurance/coverage and out-of-pocket costs (these can differ by plan).
- Past response to CGRP therapies (some people respond to one and not the other).

If you’d like, tell me:
- Are you mainly dealing with episodic or chronic migraine?
- Do you prefer monthly vs quarterly dosing?
- Any history of constipation or other GI issues?
- Are you also considering cluster headache prevention?

I can tailor a more specific comparison or help you think of questions to ask your clinician. This isn’t medical advice—please discuss with your doctor to pick the best option for you.